Ad
related to: alzheimer's news 2018 biogenTreatment for mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. Explore an available treatment option for you or your loved one & sign up for more info.
- About Treatment
Learn more about the Alzheimer's
treatment option & how it works.
- Alzheimer's Disease Info
Learn about the stages of AD and
diagnostic tests for patients.
- Support & Resources
Patient and care partner support
available on the treatment website.
- For Care Partners
Help support your loved one. View
tips and infusion companion info.
- Getting Started
Find infusion FAQs & tips for
getting started with treatment.
- Sign Up For More Info
Get access to information all about
treatment & useful tips.
- About Treatment
Search results
May 26, 2024 · LEQEMBI is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism. South Korea is the fourth country to grant approval, following approvals in the U.S., Japan, and China. It is estimated there were approximately 900,000 dementia patients in South ...
May 26, 2024 · Notes to Editors. 1. About lecanemab (LEQEMBI ®). Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). 5 Lecanemab is approved in the U.S., 6 Japan, 7 and China. 8 In the U.S., Japan and China, the ...
2 days ago · Leqembi reduced amyloid markers in early Alzheimer's disease and resulted in moderately less decline in measures of cognition and function compared to placebo. Adverse events of Leqembi included amyloid-related imaging abnormalities (ARIA) and infusion reactions. The Latest A phase 3 clinical trial funded by Eisai and Biogen investigated the effects of Leqembi in patients with
May 20, 2024 · Biogen has four other Alzheimer's candidates in its clinical pipeline behind recently-approved Aduhelm, but one of them – anti-tau antibody gosuranemab – has just been canned. The decision ...
May 16, 2024 · Damian Garde. Biogen Inc. ’s Chief Executive Officer is searching for smaller deals to expand its treatment portfolio as the company prepares for a future that he expects will be highly dependent on Alzheimer’s disease drugs. “We could spend a couple of billion this year” on deals, CEO Chris Viehbacher said in an interview at Bloomberg ...
May 15, 2024 · In April 2024, Biogen and Eisai announced that they had missed their March 2024 target to file a BLA for the subcutaneous Leqembi injection. The companies initially planned to file the rolling BLA under Leqembi’s existing Fast Track and Breakthrough Designation, but the FDA clarified that they would need a separate Fast Track designation for ...
May 16, 2024 · 2:10. Biogen Inc. ’s Chief Executive Officer is searching for smaller deals to expand its treatment portfolio as the company prepares for a future that he expects will be highly dependent on ...
Ad
related to: alzheimer's news 2018 biogenTreatment for mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. Explore an available treatment option for you or your loved one & sign up for more info.
